AngioDynamics, Inc. (ANGO) Receives Average Rating of “Hold” from Analysts

AngioDynamics, Inc. (NASDAQ:ANGO) has earned a consensus recommendation of “Hold” from the eight brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $18.00.

A number of brokerages have commented on ANGO. Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 price target on shares of AngioDynamics in a research report on Sunday, October 8th. TheStreet cut AngioDynamics from a “b-” rating to a “c” rating in a research report on Tuesday, January 2nd. Zacks Investment Research upgraded AngioDynamics from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Monday, January 8th. Craig Hallum lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Finally, KeyCorp reiterated a “hold” rating on shares of AngioDynamics in a research note on Friday, September 29th.

Shares of AngioDynamics (NASDAQ:ANGO) traded up $0.07 on Tuesday, reaching $16.35. The company’s stock had a trading volume of 144,893 shares, compared to its average volume of 251,082. AngioDynamics has a 12 month low of $14.80 and a 12 month high of $18.85. The company has a current ratio of 2.56, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. The firm has a market cap of $600.30, a PE ratio of -60.56, a P/E/G ratio of 1.57 and a beta of 1.04.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.16. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The company had revenue of $86.70 million during the quarter, compared to analysts’ expectations of $88.15 million. During the same quarter in the previous year, the firm posted $0.19 EPS. The firm’s revenue was down 2.6% compared to the same quarter last year. equities research analysts predict that AngioDynamics will post 0.69 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in shares of AngioDynamics during the 3rd quarter valued at about $143,000. Acrospire Investment Management LLC raised its stake in shares of AngioDynamics by 3.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock valued at $145,000 after buying an additional 317 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of AngioDynamics during the 3rd quarter valued at about $175,000. Teachers Retirement System of The State of Kentucky raised its stake in shares of AngioDynamics by 54.9% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 11,000 shares of the medical instruments supplier’s stock valued at $178,000 after buying an additional 3,900 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in shares of AngioDynamics by 49.3% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 14,135 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 4,668 shares during the last quarter. Institutional investors and hedge funds own 95.23% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/21/angiodynamics-inc-ango-receives-average-rating-of-hold-from-analysts.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply